BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Major Depressive Disorder readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Major Depressive Diso
 rder\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05660642-821@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:BPL-003 (mebufotenin benzoate): Phase 2 readout est. (NCT05660642)
DESCRIPTION:BPL-003 (mebufotenin benzoate)\, phase 2\, Major Depressive Dis
 order.\nStudy: An Open-Label Study to Evaluate the Safety\, Tolerability a
 nd Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depres
 sion\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bpl-003-mebufotenin-benzoate#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05660642
URL:https://assetmemo.bio/drug/bpl-003-mebufotenin-benzoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922878-807@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ALTO-300: Phase 2 readout est. (NCT05922878)
DESCRIPTION:ALTO-300\, phase 2\, Major Depressive Disorder.\nStudy: Study o
 f ALTO-300 in MDD\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/alto-300#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05922878
URL:https://assetmemo.bio/drug/alto-300#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559306-802@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Seltorexant: Phase 3 readout est. (NCT06559306)
DESCRIPTION:Seltorexant\, phase 3\, Major Depressive Disorder.\nStudy: Phas
 e 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Pa
 rticipants With Major Depressive Disorder and Insomnia Symptoms\nEstimated
  primary completion: 30 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/seltorexant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06559306
URL:https://assetmemo.bio/drug/seltorexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185815-803@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cariprazine (Vraylar): Phase 1/2 readout est. (NCT07185815)
DESCRIPTION:Cariprazine (Vraylar)\, phase 1/2\, Major Depressive Disorder.\
 nStudy: Pharmacokinetics\, Safety\, Tolerability and Efficacy of a Subcuta
 neous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects
  Eligible for Treatment With Oral Cariprazine\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cariprazine-vraylar#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185815
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226661-864@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SPN-821: Phase 2 readout est. (NCT07226661)
DESCRIPTION:SPN-821\, phase 2\, Major Depressive Disorder.\nStudy: Double-b
 lind\, Placebo-controlled Study in Adults With Major Depressive Disorder\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/spn-821#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07226661
URL:https://assetmemo.bio/drug/spn-821#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922110-819@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azetukalner: Phase 3 readout est. (NCT06922110)
DESCRIPTION:Azetukalner\, phase 3\, Major Depressive Disorder.\nStudy: An O
 pen-Label Study of Azetukalner in Major Depressive Disorder\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azetukalner#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06922110
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07065240-865@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SPT-300 (GlyphAllo (allopregnanolone prodrug)): Phase 2 readout est
 . (NCT07065240)
DESCRIPTION:SPT-300 (GlyphAllo (allopregnanolone prodrug))\, phase 2\, Majo
 r Depressive Disorder.\nStudy: A Study to Evaluate the Efficacy and Safety
  of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder\, W
 ith or Without Anxious Distress (BUOY-1 Study)\nEstimated primary completi
 on: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/glyph
 allo-allopregnanolone-prodrug#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07065240
URL:https://assetmemo.bio/drug/glyphallo-allopregnanolone-prodrug#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850689-872@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT05850689)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: Study of Lumateperone as Adjunctive Therapy in the Treatment of Pat
 ients With Major Depressive Disorder\nEstimated primary completion: 5 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0585
 0689
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161700-865@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:SPT-300 (GlyphAllo (allopregnanolone prodrug)): Phase 2 readout est
 . (NCT07161700)
DESCRIPTION:SPT-300 (GlyphAllo (allopregnanolone prodrug))\, phase 2\, Majo
 r Depressive Disorder.\nStudy: An Open-Label Extension Study to Evaluate t
 he Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Maj
 or Depressive Disorder\, With or Without Anxious Distress (BUOY-1 OLE Stud
 y)\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/glyphallo-allopregnanolone-prodrug#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07161700
URL:https://assetmemo.bio/drug/glyphallo-allopregnanolone-prodrug#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610473-826@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:DT-101: Phase 2 readout est. (NCT07610473)
DESCRIPTION:DT-101\, phase 2\, Major Depressive Disorder.\nStudy: A Study t
 o Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patie
 nts With Depression\nEstimated primary completion: May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dt-101#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07610473
URL:https://assetmemo.bio/drug/dt-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076407-819@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Azetukalner: Phase 3 readout est. (NCT07076407)
DESCRIPTION:Azetukalner\, phase 3\, Major Depressive Disorder.\nStudy: A Ra
 ndomized Study of Azetukalner Versus Placebo in Major Depressive Disorder 
 (X-NOVA3)\nEstimated primary completion: May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/azetukalner#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07076407
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793397-824@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:Deupsilocin: Phase 3 readout est. (NCT06793397)
DESCRIPTION:Deupsilocin\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressi
 ve Disorder\nEstimated primary completion: 7 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/deupsilocin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06793397
URL:https://assetmemo.bio/drug/deupsilocin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04984512-833@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Mitizodone phosphate: Phase 2/3 readout est. (NCT04984512)
DESCRIPTION:Mitizodone phosphate\, phase 2/3\, Major Depressive Disorder.\n
 Study: The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Trea
 tment of Patient With Major Depressive Disorder\nEstimated primary complet
 ion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitiz
 odone-phosphate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04984512
URL:https://assetmemo.bio/drug/mitizodone-phosphate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786624-810@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06786624)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: Stud
 y to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatm
 ent in Participants With Major Depressive Disorder (MDD)\nEstimated primar
 y completion: July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/osavampator#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06786624
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911112-810@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06911112)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06911112
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963021-810@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06963021)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963021
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284667-815@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:ACP-211: Phase 2 readout est. (NCT07284667)
DESCRIPTION:ACP-211\, phase 2\, Major Depressive Disorder.\nStudy: ACP-211 
 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant R
 esponse\nEstimated primary completion: August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/acp-211#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07284667
URL:https://assetmemo.bio/drug/acp-211#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07300969-826@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:DT-101: Phase 2 readout est. (NCT07300969)
DESCRIPTION:DT-101\, phase 2\, Major Depressive Disorder.\nStudy: A Study t
 o Evaluate the Effectiveness of DT-101 in Patients With Depression\nEstima
 ted primary completion: August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dt-101#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07300969
URL:https://assetmemo.bio/drug/dt-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276997-837@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Icalcaprant: Phase 2 readout est. (NCT07276997)
DESCRIPTION:Icalcaprant\, phase 2\, Major Depressive Disorder.\nStudy: A St
 udy to Assess Change in Disease Activity and Adverse Events of Oral Icalca
 prant in Adult Participants With Major Depressive Disorder\nEstimated prim
 ary completion: September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/icalcaprant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07276997
URL:https://assetmemo.bio/drug/icalcaprant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547489-869@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Zelquistinel: Phase 2 readout est. (NCT06547489)
DESCRIPTION:Zelquistinel\, phase 2\, Major Depressive Disorder.\nStudy: Zel
 quistinel or Placebo for the Reduction of Symptoms of Major Depressive Dis
 order\nEstimated primary completion: September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/zelquistinel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06547489
URL:https://assetmemo.bio/drug/zelquistinel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592689-827@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:DT120 (Lysergide tartrate (LSD)): Phase 3 readout est. (NCT07592689
 )
DESCRIPTION:DT120 (Lysergide tartrate (LSD))\, phase 3\, Major Depressive D
 isorder.\nStudy: A Phase 3 Trial of DT120 for Major Depressive Disorder (A
 scend)\nEstimated primary completion: September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lysergide-tartrate-lsd#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07592689
URL:https://assetmemo.bio/drug/lysergide-tartrate-lsd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06828887-841@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:LV232: Phase 2 readout est. (NCT06828887)
DESCRIPTION:LV232\, phase 2\, Major Depressive Disorder.\nStudy: Dose-Findi
 ng Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in
  the Treatment of MDD\nEstimated primary completion: 1 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lv232#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06828887
URL:https://assetmemo.bio/drug/lv232#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553637-806@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pramipexole/ondansetron (ALTO-207): Phase 2 readout est. (NCT075536
 37)
DESCRIPTION:Pramipexole/ondansetron (ALTO-207)\, phase 2\, Major Depressive
  Disorder.\nStudy: ALTO-207 in Adults With Treatment-resistant Depression 
 (TRD)\nEstimated primary completion: November 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pramipexole-ondansetron-alto-207#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07553637
URL:https://assetmemo.bio/drug/pramipexole-ondansetron-alto-207#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741240-839@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KH607: Phase 3 readout est. (NCT07741240)
DESCRIPTION:KH607\, phase 3\, Major Depressive Disorder.\nStudy: A Study of
  KH607 as Monotherpy in Adults Participants With Major Depressive Disorder
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/kh607#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07741240
URL:https://assetmemo.bio/drug/kh607#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741331-839@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KH607: Phase 3 readout est. (NCT07741331)
DESCRIPTION:KH607\, phase 3\, Major Depressive Disorder.\nStudy: Compare th
 e Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Ta
 blets in Adult Patients With Major Depressive Disorder\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/kh607#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07741331
URL:https://assetmemo.bio/drug/kh607#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227103-849@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:D-cycloserine/lurasidone (NRX-101): Phase 2/3 readout est. (NCT0722
 7103)
DESCRIPTION:D-cycloserine/lurasidone (NRX-101)\, phase 2/3\, Major Depressi
 ve Disorder.\nStudy: A Randomized\, Double-Blind Controlled Comparison of 
 NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Mag
 netic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/d-cycloserine-lurasidone-nrx-101#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07227103
URL:https://assetmemo.bio/drug/d-cycloserine-lurasidone-nrx-101#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621237-867@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tonmya (cyclobenzaprine): Phase 2 readout est. (NCT07621237)
DESCRIPTION:Tonmya (cyclobenzaprine)\, phase 2\, Major Depressive Disorder.
 \nStudy: A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Part
 icipants With Major Depressive Disorder (MDD)\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cyc
 lobenzaprine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07621237
URL:https://assetmemo.bio/drug/cyclobenzaprine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412756-822@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07412756)
DESCRIPTION:Brenipatide\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide in Adult Participants With Major Depressive Disorder\nE
 stimated primary completion: February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07412756
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03833206-853@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:PDC-1421: Phase 1/2 readout est. (NCT03833206)
DESCRIPTION:PDC-1421\, phase 1/2\, Major Depressive Disorder.\nStudy: A Pha
 se I/II Study of PDC-1421 for Treating Depression in Cancer Patients\nEsti
 mated primary completion: 28 February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pdc-1421#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03833206
URL:https://assetmemo.bio/drug/pdc-1421#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830044-9305@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Milsaperidone (VHX-896): Phase 3 readout est. (NCT06830044)
DESCRIPTION:Milsaperidone (VHX-896)\, phase 3\, Major Depressive Disorder.\
 nStudy: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive T
 herapy in Patients With Major Depressive Disorder\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mi
 lsaperidone-vhx-896#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06830044
URL:https://assetmemo.bio/drug/milsaperidone-vhx-896#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115329-869@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Zelquistinel: Phase 2 readout est. (NCT07115329)
DESCRIPTION:Zelquistinel\, phase 2\, Major Depressive Disorder.\nStudy: A P
 hase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of M
 ajor Depressive Disorder\nEstimated primary completion: 30 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zelquistinel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07115329
URL:https://assetmemo.bio/drug/zelquistinel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928245-822@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07928245)
DESCRIPTION:Brenipatide\, phase 2\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide in Participants With Major Depressive Disorder\nEstimat
 ed primary completion: May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07928245
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623135-872@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT07623135)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: Lumateperone for Late-Life Depression\nEstimated primary completion
 : June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumatepe
 rone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07623135
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06605105-824@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Deupsilocin: Phase 3 readout est. (NCT06605105)
DESCRIPTION:Deupsilocin\, phase 3\, Major Depressive Disorder.\nStudy: Phas
 e III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in
  MDD (EXTEND)\nEstimated primary completion: 6 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/deupsilocin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06605105
URL:https://assetmemo.bio/drug/deupsilocin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196501-810@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Osavampator: Phase 3 readout est. (NCT07196501)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Tre
 atment in Participants With Major Depressive Disorder (MDD)\nEstimated pri
 mary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/osavampator#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07196501
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573176-802@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280824
DTEND;VALUE=DATE:20280825
SUMMARY:Seltorexant: Phase 3 readout est. (NCT07573176)
DESCRIPTION:Seltorexant\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Seltorexant as Monotherapy in Adults and Elderly Participants With 
 Major Depressive Disorder\nEstimated primary completion: 24 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/seltorexant#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07573176
URL:https://assetmemo.bio/drug/seltorexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820723-824@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Deupsilocin: Phase 2 readout est. (NCT06820723)
DESCRIPTION:Deupsilocin\, phase 2\, Major Depressive Disorder.\nStudy: A Me
 chanistic Study to Assess a Single Dose of CYB003 in Participants With Dep
 ression and Anxiety\nEstimated primary completion: November 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deupsilocin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06820723
URL:https://assetmemo.bio/drug/deupsilocin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772531-11181@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281106
DTEND;VALUE=DATE:20281107
SUMMARY:Evifacotrep: Phase 2 readout est. (NCT07772531)
DESCRIPTION:Evifacotrep\, phase 2\, Major Depressive Disorder.\nStudy: A St
 udy to Evaluate BMS-986511 in Adults With Major Depressive Disorder\nEstim
 ated primary completion: 6 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/evifacotrep#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07772531
URL:https://assetmemo.bio/drug/evifacotrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775300-822@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07775300)
DESCRIPTION:Brenipatide\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide (LY3537031) in Adult Participants With Major Depressive
  Disorder\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07775300
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484217-866@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07484217)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Major Depressive Disorder.\nS
 tudy: Clinical Assessment of Response in the Treatment of Depression With 
 Daytime Sleepiness Using Solriamfetol\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/solriamfeto
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 484217
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716098-800@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Spravato (Esketamine): Phase 3 readout est. (NCT07716098)
DESCRIPTION:Spravato (Esketamine)\, phase 3\, Major Depressive Disorder.\nS
 tudy: A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Part
 icipants With Treatment-resistant Depression\nEstimated primary completion
 : 27 December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 sketamine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07716098
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07810738-9212@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Aripiprazole (Abilify): Phase 2 readout est. (NCT07810738)
DESCRIPTION:Aripiprazole (Abilify)\, phase 2\, Major Depressive Disorder.\n
 Study: The BAARD Study : Evaluating a Computerized Approach to Treatment S
 election in Older Adults With Treatment Resistant Depression.\nEstimated p
 rimary completion: 15 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/aripiprazole-abilify#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07810738
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966401-810@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Osavampator: Phase 3 readout est. (NCT06966401)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: Long
 -Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adj
 unctive Treatment in Participants With Major Depressive Disorder (MDD)\nEs
 timated primary completion: May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/osavampator#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06966401
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747389-872@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT07747389)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: A Study of Lumateperone Versus Placebo in Participants With Major D
 epressive Disorder\nEstimated primary completion: 20 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07747389
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204314-845@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trintellix (Vortioxetine): Phase 3 readout est. (NCT07204314)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 3\, Major Depressive Disorder
 .\nStudy: A Study of Vortioxetine in Japanese Pediatric Patients With Majo
 r Depressive Disorder\nEstimated primary completion: 30 September 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vortioxetine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07204314
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132178-855@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Psilocybin (COMP360): Phase 2 readout est. (NCT06132178)
DESCRIPTION:Psilocybin (COMP360)\, phase 2\, Major Depressive Disorder.\nSt
 udy: Psilocybin rTMS for Treatment Resistant Depression\nEstimated primary
  completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/psilocybin-comp360#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06132178
URL:https://assetmemo.bio/drug/psilocybin-comp360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226232-855@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20301202
DTEND;VALUE=DATE:20301203
SUMMARY:Psilocybin (COMP360): Phase 3 readout est. (NCT07226232)
DESCRIPTION:Psilocybin (COMP360)\, phase 3\, Major Depressive Disorder.\nSt
 udy: Psilocybin Intervention for Veterans Overcoming Treatment-Resistant D
 epression\nEstimated primary completion: 2 December 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/psilocybin-comp360#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07226232
URL:https://assetmemo.bio/drug/psilocybin-comp360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227454-800@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20310409
DTEND;VALUE=DATE:20310410
SUMMARY:Spravato (Esketamine): Phase 3 readout est. (NCT07227454)
DESCRIPTION:Spravato (Esketamine)\, phase 3\, Major Depressive Disorder.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of Esketamine for Reduct
 ion of Symptoms of Major Depressive Disorder\nEstimated primary completion
 : 9 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/esket
 amine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07227454
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
